Skip to main content
Menu Search & Directory

Cancer Clinical Trials

SLUCare specialists in hematology, oncology and cellular therapy are committed to leadership in clinical research programs. As the faculty of Saint Louis University School of Medicine, our staff regulary conducts clinical trials of new medicines and technologies. The following studies are now seeking participants.

Defining how patient BMI influences the response to immunotherapy for cancer

Dr. Ryan Teague

A study to determine how immunotherapy influences BMI in patients with any cancer planned to receive Pembrolizumab, Atezolizumab, Ipilimumab, Nivolumab, or Durvalumab

 

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Alliance/ A051301 - Dr. Mark Fesler

A randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype

 

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

ECOG-ACRIN/ EA4151 - Dr. Mark Fesler

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

 

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

SeattleGenetics/ SGN-028 - Dr. Mark Fesler

A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classic Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (PTCL)

 

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)

TG Therapeutics/ UTX-TGR-205 - Dr. Sagun Goyal

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma

 

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Merck/ LEAP-012: MK7902-012 - Dr. John Richart

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma

 

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Astex/Covance / ASTX660 - Dr. Mark Fesler

Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas